Efficacy, drug sustainability, and safety of ustekinumab treatment in Crohn’s disease patients over three years
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
Efficacy, drug sustainability, and safety of ustekinumab treatment in Crohn’s disease patients over three years ; volume:14 ; number:1 ; day:28 ; month:6 ; year:2024 ; pages:1-8 ; date:12.2024
Scientific reports ; 14, Heft 1 (28.6.2024), 1-8, 12.2024
- Urheber
-
Barkai, Laszlo J.
Gonczi, Lorant
Balogh, Fruzsina
Angyal, Dorottya
Farkas, Klaudia
Farkas, Bernadett
Molnar, Tamas
Szamosi, Tamas
Schafer, Eszter
Golovics, Petra A.
Juhasz, Mark
Patai, Arpad
Vincze, Aron
Sarlos, Patricia
Farkas, Alexandra
Dubravcsik, Zsolt
Toth, Tamas G.
Szekely, Hajnal
Miheller, Pal
Lakatos, Peter L.
Ilias, Akos
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1038/s41598-024-65987-1
- URN
-
urn:nbn:de:101:1-2409230943338.875564532974
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:20 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Barkai, Laszlo J.
- Gonczi, Lorant
- Balogh, Fruzsina
- Angyal, Dorottya
- Farkas, Klaudia
- Farkas, Bernadett
- Molnar, Tamas
- Szamosi, Tamas
- Schafer, Eszter
- Golovics, Petra A.
- Juhasz, Mark
- Patai, Arpad
- Vincze, Aron
- Sarlos, Patricia
- Farkas, Alexandra
- Dubravcsik, Zsolt
- Toth, Tamas G.
- Szekely, Hajnal
- Miheller, Pal
- Lakatos, Peter L.
- Ilias, Akos
- SpringerLink (Online service)
Ähnliche Objekte (12)
Posterior Reversible Encephalopathy Syndrome following Ustekinumab Induction for Crohn’s Disease
Elderly-onset Crohn’s disease remarkably responsive to ustekinumab: a case report
Successful Drug Desensitization to Ustekinumab in a Patient with Crohn’s Disease
The Efficacy of Combination Therapy with Ustekinumab and Budesonide for Crohn’s Disease: A Randomized Controlled Trial
Safety and Efficacy of Ustekinumab in the Treatment of Crohn Disease: A Systematic Review and Meta-analysis
Ustekinumab inhibits T follicular helper cell differentiation in patients with Crohn’s disease
Cost-effectiveness of ustekinumab in moderate to severe Crohn’s disease in Sweden
Ustekinumab Trough Concentrations Are Associated with Biochemical Outcomes in Patients with Crohn’s Disease
Ustekinumab trough levels predicting laboratory and endoscopic remission in patients with Crohn’s disease
Psoriasis, Psoriasis-Arthritis und Morbus Crohn : Ustekinumab zeigt langfristige Wirksamkeit und gutes Safety-Profil
Ustekinumab Safety in Psoriasis, Psoriatic Arthritis, and Crohn’s Disease: An Integrated Analysis of Phase II/III Clinical Development Programs
Pustular Rash in Crohn’s Patient on Ustekinumab Raises Concern for Drug-Induced Paradoxical Psoriasis
Posterior Reversible Encephalopathy Syndrome following Ustekinumab Induction for Crohn’s Disease
Elderly-onset Crohn’s disease remarkably responsive to ustekinumab: a case report
Successful Drug Desensitization to Ustekinumab in a Patient with Crohn’s Disease
The Efficacy of Combination Therapy with Ustekinumab and Budesonide for Crohn’s Disease: A Randomized Controlled Trial
Safety and Efficacy of Ustekinumab in the Treatment of Crohn Disease: A Systematic Review and Meta-analysis
Ustekinumab inhibits T follicular helper cell differentiation in patients with Crohn’s disease
Cost-effectiveness of ustekinumab in moderate to severe Crohn’s disease in Sweden
Ustekinumab Trough Concentrations Are Associated with Biochemical Outcomes in Patients with Crohn’s Disease
Ustekinumab trough levels predicting laboratory and endoscopic remission in patients with Crohn’s disease
Psoriasis, Psoriasis-Arthritis und Morbus Crohn : Ustekinumab zeigt langfristige Wirksamkeit und gutes Safety-Profil
Ustekinumab Safety in Psoriasis, Psoriatic Arthritis, and Crohn’s Disease: An Integrated Analysis of Phase II/III Clinical Development Programs
Pustular Rash in Crohn’s Patient on Ustekinumab Raises Concern for Drug-Induced Paradoxical Psoriasis
Posterior Reversible Encephalopathy Syndrome following Ustekinumab Induction for Crohn’s Disease
Elderly-onset Crohn’s disease remarkably responsive to ustekinumab: a case report
Successful Drug Desensitization to Ustekinumab in a Patient with Crohn’s Disease
The Efficacy of Combination Therapy with Ustekinumab and Budesonide for Crohn’s Disease: A Randomized Controlled Trial
Safety and Efficacy of Ustekinumab in the Treatment of Crohn Disease: A Systematic Review and Meta-analysis
Ustekinumab inhibits T follicular helper cell differentiation in patients with Crohn’s disease
Cost-effectiveness of ustekinumab in moderate to severe Crohn’s disease in Sweden
Ustekinumab Trough Concentrations Are Associated with Biochemical Outcomes in Patients with Crohn’s Disease
Ustekinumab trough levels predicting laboratory and endoscopic remission in patients with Crohn’s disease
Psoriasis, Psoriasis-Arthritis und Morbus Crohn : Ustekinumab zeigt langfristige Wirksamkeit und gutes Safety-Profil
Ustekinumab Safety in Psoriasis, Psoriatic Arthritis, and Crohn’s Disease: An Integrated Analysis of Phase II/III Clinical Development Programs